101. Race, medicine, and social justice: pharmacogenetics, diversity, and the case of BiDil
- Author
-
Jordan, Sara R.
- Subjects
Isosorbide dinitrate -- Complications and side effects -- Ethical aspects ,Medical policy -- Analysis ,Social justice -- Analysis ,Drug therapy, Combination -- Complications and side effects -- Analysis ,Hydralazine -- Complications and side effects -- Ethical aspects ,Pharmacogenetics -- Analysis -- Ethical aspects ,Race discrimination -- Analysis ,Political science ,Social sciences ,Bidil (Medication) -- Complications and side effects -- Ethical aspects - Abstract
In this article, I probe an example of high-technology medicine as a case study in the problems of the regulation of advancing technology. Specifically, I address the implications of pharmacogenomics--an emerging form of population-based health care intervention--for public policies designed to eliminate racial disparities in health. Using the case of BiDil, a historical precursor to pharmacogenetic technology, I offer a framework for further studies of high-technology medicine in which policy analysis is part of a social review based on the justice standard of ex ante mutual advantage. It is the contention in this article that the most just and reasonable deployment of pharmacogenomics is as a compensatory tool to alleviate health disparities. KEY WORDS: health policy, pharmacogenetics, racial disparities, social justice, Introduction Does the selective use of advanced medical technology to benefit one group over the other contradict the goals of justice? This question spurs the efforts of bioethicists, scholars of [...]
- Published
- 2008